Monoclonal Antibody Therapy and Docetaxel in Treating Women With Metastatic or Recurrent Breast Cancer

NCT00028483 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

INDUSTRY

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: cBR96-doxorubicin immunoconjugate
DRUG: docetaxel

Sponsor

Seagen Inc.